Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia

Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Miguel A. Sanz, Martin S. Tallman, Francesco Lo-Coco Oncologist 2005; 10: 806-814 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the clinical and biological prognostic factors for Wilms' tumor. Discuss the different treatment strategies and staging systems adopted in North America and Europe. Explain the challenges and treatment approaches for anaplastic, bilateral, and recurrent Wilms' tumor. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 28, 2005 Most Recent Review: Nov. 28, 2005* Most Recent Update: Nov. 28, 2005 Date Credit Expires: Nov. 28, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.